Daito Pharmaceutical Co.,Ltd. (4577.T) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	51.2B	50.6B	46.9B	45.1B	43.5B
Cost of Revenue	10.5B	42.0B	37.1B	34.8B	32.0B
Gross Profit	2.6B	8.6B	9.8B	10.3B	11.5B
Operating Expenses
R&D Expense	—	—	—	—	—
SG&A Expense	1.6B	6.0B	5.9B	5.1B	4.9B
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	—	—	—	—	—
Total Operating Expenses	1.6B	6.0B	5.9B	5.1B	4.9B
Cost and Expenses	48.4B	48.0B	43.0B	39.9B	36.9B
Operating Income (EBIT)	2.8B	2.6B	3.9B	5.2B	6.6B
Non-Operating
Interest Income	—	1.0M	—	—	—
Interest Expense	30.0M	123.0M	41.0M	12.0M	9.0M
Net Interest Income	(30.0M)	(122.0M)	(41.0M)	(12.0M)	(9.0M)
Other Non-Op Income/Expense	55.0M	85.0M	29.0M	(38.0M)	176.0M
Non-Operating Income (excl Interest)	132.0M	244.0M	126.0M	86.0M	205.0M
EBT (Pre-Tax Income)	1.1B	3.0B	4.2B	5.1B	6.7B
Income Tax Expense	377.0M	1.2B	1.0B	1.5B	2.1B
Bottom Line
Net Income	2.2B	1.9B	3.3B	3.6B	4.7B
Earnings from Cont. Ops	—	—	—	—	—
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	2.2B	1.9B	3.3B	3.6B	4.7B
Per Share
Basic EPS	¥84	¥63	¥210	¥250	¥335
Diluted EPS	¥84	—	—	¥250	—
Revenue Per Share	¥1,716	¥1,665	¥2,989	¥3,137	¥3,123
Shares
Basic Shares Outstanding	29.8M	30.4M	15.7M	14.4M	13.9M
Diluted Shares Outstanding	—	—	—	—	—
Profitability Metrics
EBITDA	—	7.0B	7.6B	9.1B	9.9B
D&A	—	4.3B	3.7B	3.9B	3.3B
EBIT	2.8B	2.6B	3.9B	5.2B	6.6B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Feb 1, 2026